A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer
A phase 1/2 trial of SHR-A2102, Adebrelimab, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
Overview
A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT06512051 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 248 participants planned, started 2024-07-30 and due to reach its primary completion in 2026-10. Interventions recorded: SHR-A2102 for Injection, Adebrelimab Injection, Cisplatin injection, Carboplatin injection, Bevacizumab Injection. Conditions listed: Advanced or Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin.
- TrialA Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
- TrialA Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
- TrialA Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer.
- TrialA Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin.
- TrialA Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Carboplatin, Small-cell lung cancer.
- TrialClinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals.
- TrialA Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin.